MAY 16, 2021 9:34 AM PDT

Can you guess which drug is both antiviral and immunotherapeutic?

Hepatitis B virus (HBV) is the most common cause of liver cancer in the world, resulting in approximately 880,000 deaths from liver cirrhosis and hepatocellular carcinoma/liver cancer (HCC) combined. Now new research from UCL shows it is possible to use immunotherapy to treat chronic HBV. The study was published recently in Nature Communications

Lead author Professor Mala Maini of the UCL Division of Infection & Immunity commented: "Chronic hepatitis B virus infection is a major global health problem and the most common cause of liver cancer in the world. The development of novel therapeutic options is crucial to improve patient care. Immune cells such as T cells are indispensable for fighting viruses and tumors but are often highly dysfunctional and fail to control these diseases. The current standard of care treatments are often incapable of eliminating the virus, do not prevent cancer development, and do not rescue immune cells. In this study, we aimed to identify a treatment target to directly inhibit the virus while also boosting the immune cells fighting it."

The newly developed immunotherapy targets an enzyme called acyl-CoA:cholesterol acyltransferase (referred to as ACAT) to elicit an immune response. ACAT plays a role in managing levels of cholesterol in cells and by inhibiting it, it is possible to amp up specific immune cells to attack both cancer cells and the virus itself. 

First author Dr. Nathalie Schmidt explained: "We have found a highly effective novel target for the treatment of chronic hepatitis B virus infection and liver cancer. Modulating cholesterol metabolism with ACAT inhibitors has the unique features of directly targeting the virus and tumors while at the same time boosting the T cells that fight them. This enables us to tackle the disease from multiple directions at the same time."

The best part, adds Dr. Schmidt, is that it’s possible to use an already-approved drug that has both antiviral and immunotherapeutic effects. "The cholesterol-modifying drug is already known to be safe in humans and we hope that our study now informs the development of clinical trials combining cholesterol modulation with other immunotherapies. In summary, our findings offer exciting new possibilities for the treatment of patients with chronic viral infections and cancer."

Sources: Nature Communications, Science Daily

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
APR 03, 2021
Drug Discovery & Development
Why Are Some Cancer Therapeutics Ineffective?
APR 03, 2021
Why Are Some Cancer Therapeutics Ineffective?
Why don’t some cancer therapeutics not work in humans when they were successful in mice? The answer to this questi ...
APR 14, 2021
Cancer
Fighting back against medulloblastoma with naturally-occurring compound
APR 14, 2021
Fighting back against medulloblastoma with naturally-occurring compound
Renewed hope for young children with medulloblastoma comes in the form of a research paper published from the Queen Mary ...
APR 10, 2021
Cancer
Administration of this immune-stimulating drug pre-surgery could help pancreatic cancer patients
APR 10, 2021
Administration of this immune-stimulating drug pre-surgery could help pancreatic cancer patients
New findings support the administration of a CD40 immune-stimulating drug to early-stage pancreatic cancer patients in a ...
MAY 05, 2021
Immunology
Novel 3D Bio-printed Leukemia Model Shows Potential for Treatment Testing Platform
MAY 05, 2021
Novel 3D Bio-printed Leukemia Model Shows Potential for Treatment Testing Platform
Three-dimensional (3D) printing has become a common technique over the past two decades. Now, the technique has been ado ...
MAY 09, 2021
Cancer
Vegetarian diet shows low levels of disease-related biomarkers
MAY 09, 2021
Vegetarian diet shows low levels of disease-related biomarkers
Researchers from the University of Glasgow have conducted a study on biomarkers in order to glean more information on th ...
JUN 04, 2021
Cancer
Cancer patients with COVID-19 fare better with remote health monitoring
JUN 04, 2021
Cancer patients with COVID-19 fare better with remote health monitoring
A new study presented last week at the American Society of Clinical Oncology Annual Meeting after its publication in the ...
Loading Comments...